Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects-Reference-Cited by-同舟云学术

Multiple-Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects

Published:2004-05 Issue:5 Volume:44 Page:532-537
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Kovarik John M.,Schmouder Robert,Barilla Denise,Riviere Gilles-Jacques,Wang Yibin,Hunt Thomas

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1177/0091270004264165/fullpdf

Reference8 articles.

1. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity;Brinkmann;Curr Opin Immunol,2002

2. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases;Kovarik;Expert Opin Emerging Drugs,2003

3. FTY720: altered lymphocyte traffic results in allograft protection;Brinkmann;Transplantation,2001

4. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory;Pinschewer;J Immunol,2000

5. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12-month preliminary results [abstract];Ferguson;Am J Transplant,2003

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia;Frontiers in Immunology;2024-06-17

2. Fingolimod (FTY720), an FDA‐approved sphingosine 1‐phosphate (S1P) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection;IUBMB Life;2023-11-30

3. Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?;Neurology and Therapy;2023-05-17

4. Dose-dependent reduction of lymphocyte count and heart rate after multiple administration of LC51-0255, a novel sphingosine-1-phosphate receptor 1 modulator, in healthy subjects;Frontiers in Pharmacology;2022-08-22

5. Single‐dose of LC51‐0255, a selective S1P ₁ receptor modulator, showed dose‐dependent and reversible reduction of absolute lymphocyte count in humans;Clinical and Translational Science;2022-01-23